Year-end Sale % OFF 
Abstract
Current guidelines for the management of atrial fibrillation (AF) recommend using anticoagulants as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often prescribed to elderly patients. Review of clinical and pharmacoepidemiological studies allows us to conclude that risk associated with acetylsalicylic acid (ASA) use in patients ≥75 years can overweigh its potential benefit. Other antiplatelet drugs are poorly studied in patients with AF. Dual antiplatelet therapy (ASA + clopidogrel) can be prescribed to elderly patients with cardiovascular comorbidity who are deemed unsuitable candidates for anticoagulant therapy for reasons other than bleeding risk or those who refuse to take oral anticoagulants. Combined therapy of antiplatelet drugs with warfarin or new oral anticoagulants results in no reduction in stroke rate compared with anticoagulant monotherapy but is associated with increased risk of bleeding and can’t be recommended.
Highlights
В современных руководствах по лечению фибрилляции предсердий (ФП) в качестве препаратов выбора для профилактики инсульта рекомендуют антикоагулянты, однако в реальной медицинской практике пожилым пациентам часто назначают антиагреганты
Current guidelines for the management of atrial fibrillation (AF) recommend using anticoagulants as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often prescribed to elderly patients
Review of clinical and pharmacoepidemiological studies allows us to conclude that risk associated with acetylsalicylic acid (ASA) use in patients ≥75 years can overweigh its potential benefit
Summary
В современных руководствах по лечению фибрилляции предсердий (ФП) в качестве препаратов выбора для профилактики инсульта рекомендуют антикоагулянты, однако в реальной медицинской практике пожилым пациентам часто назначают антиагреганты. Согласно обобщенным данным 12 РКИ (n=12963), включенных в мета-анализа Hartetal, риск развития инсульта при применении АСК статистически незначимо снижается по отношению к плацебо на 19% [9], причем на полученные результаты значительное влияние оказало исследование (Stroke Preventionin Atrial Fibrillation Study), в котором снижение риска инсульта у больных, получавших АСК, составило 42% (3,6% в год) [10].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
